Literature DB >> 7988298

Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction. A report from the multicenter trial: DIGAMI.

K A Malmberg1, S Efendic, L E Rydén.   

Abstract

OBJECTIVE: To investigate the effect of insulin-glucose infusion on metabolic control and hypoglycemic episodes and its feasibility and safety in patients with diabetes and myocardial infarction (MI) compared with conventional treatment. RESEARCH DESIGN AND METHODS: Of 327 patients with suspected acute MI 158 were randomized to insulin-glucose infusion for at least 24 h and 169 received conventional therapy. We determined the 24-h blood glucose profile in the infusion group, the degree of metabolic control, hypoglycemic events, and in-hospital complications within the two study groups.
RESULTS: Blood glucose fell from 14.6 +/- 2.9 to 9.2 +/- 2.9 mM during the first 24 h in patients receiving insulin-glucose and from 15.8 +/- 4.3 to 12.0 +/- 4.4 mM in control patients (P < 0.01). Serum potassium decreased 0.21 +/- 0.56 mM in the infusion group (P < 0.001) and 0.11 +/- 0.59 mM in the control group (P < 0.05). The difference between the groups was not significant. Twenty-eight of the 158 patients developed an episode of hypoglycemia (blood glucose < 3.0 mM) during the insulin-glucose infusion. There were no significant differences in the number of episodes of ventricular tachyarrhythmias or in ischemic events between patients with and without hypoglycemia.
CONCLUSIONS: The protocol outlined in this study gives more rapid and better metabolic control than does conventional treatment. This treatment seems to be a feasible alternative for clinical attempts. Before it can be recommended for general use, the impact on mortality needs to be evaluated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988298     DOI: 10.2337/diacare.17.9.1007

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

Review 1.  Management of hyperglycemia in hospitalized patients.

Authors:  Dawn Smiley; Guillermo E Umpierrez
Journal:  Ann N Y Acad Sci       Date:  2010-10-29       Impact factor: 5.691

2.  Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury--studies in an animal model.

Authors:  Chuan-an Shen; Shawn Fagan; Alan J Fischman; Edward E Carter; Jia-Ke Chai; Xiao-Ming Lu; Yong-Ming Yu; Ronald G Tompkins
Journal:  Surgery       Date:  2011-02-05       Impact factor: 3.982

3.  Glucose and potassium derangements by glucose-insulin-potassium infusion in acute myocardial infarction.

Authors:  I C C van der Horst; J R Timmer; J-P Ottervanger; H J G Bilo; K Miedema; R O B Gans; M-J de Boer; M Vogelzang; M W N Nijsten; F Zijlstra
Journal:  Neth Heart J       Date:  2006-03       Impact factor: 2.380

Review 4.  The Impact of Hypoglycemic Therapy on the Prognosis for Acute Coronary Syndrome in Patients with Type 2 Diabetes.

Authors:  K Yu Nikolaev; A I Shevela; S V Mustafina; O D Rymar; A K Ovsyannikova; E M Zelenskaya; A Y Kovaleva; G I Lifshits
Journal:  J Pers Med       Date:  2022-05-22

Review 5.  Hyperglycaemia in critically ill patients: marker or mediator of mortality?

Authors:  Anouk M Corstjens; Iwan C C van der Horst; Jan G Zijlstra; A B Johan Groeneveld; Felix Zijlstra; Jaap E Tulleken; Jack J M Ligtenberg
Journal:  Crit Care       Date:  2006-06-27       Impact factor: 9.097

Review 6.  Towards a feasible algorithm for tight glycaemic control in critically ill patients: a systematic review of the literature.

Authors:  Sofie Meijering; Anouk M Corstjens; Jaap E Tulleken; John H J M Meertens; Jan G Zijlstra; Jack J M Ligtenberg
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

7.  Treating Diabetes Mellitus: Pharmacophore Based Designing of Potential Drugs from Gymnema sylvestre against Insulin Receptor Protein.

Authors:  Mohammad Uzzal Hossain; Md Arif Khan; S M Rakib-Uz-Zaman; Mohammad Tuhin Ali; Md Saidul Islam; Chaman Ara Keya; Md Salimullah
Journal:  Biomed Res Int       Date:  2016-02-28       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.